33 Recruiting Studies Using Teclistamab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Teclistamab
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Hematological Malignancies
View Study & Checklist ➔MMRC Horizon One: RRMM (MMRC-099)
📍 City of Hope — Duarte, California
Relapse Multiple Myeloma
View Study & Checklist ➔A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
📍 Alaska Oncology and Hematology LLC — Anchorage, Alaska
Relapsed or Refractory Multiple Myeloma
View Study & Checklist ➔A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
📍 UCSF Fresno — Clovis, California
Multiple Myeloma
View Study & Checklist ➔A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
📍 Colorado Blood Cancer Institute — Denver, Colorado
Relapsed/ Refractory Multiple Myeloma
View Study & Checklist ➔A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham, Comprehensive Cancer Center — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Multiple Myeloma
View Study & Checklist ➔A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
📍 City of Hope — Duarte, California
Multiple Myeloma
View Study & Checklist ➔A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
📍 City of Hope National Medical Center — Duarte, California
Multiple Myeloma
View Study & Checklist ➔Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
📍 City of Hope — Duarte, California
Hematological Malignancies
View Study & Checklist ➔A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
📍 University of Arizona Cancer Center /ID# 285339 — Tucson, Arizona
Relapsed or Refractory Multiple Myeloma
View Study & Checklist ➔MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
Multiple Myeloma (MM)
View Study & Checklist ➔Teclistamab In Waldenstrom's Macroglobulinemia
📍 Massachusetts General Hospital — Boston, Massachusetts
Waldenstrom's Macroglobulinemia
View Study & Checklist ➔Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
📍 University of Miami — Miami, Florida
Multiple Myeloma
View Study & Checklist ➔Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
📍 Yale University — New Haven, Connecticut
Multiple Myeloma
View Study & Checklist ➔A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 Alabama Oncology — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔Teclistamab-Daratumumab in AL Amyloidosis
📍 Boston Medical Center — Boston, Massachusetts
Amyloid Light-chain Amyloidosis
View Study & Checklist ➔Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Recurrent Multiple Myeloma
View Study & Checklist ➔A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
📍 Mayo Clinic Phoenix — Phoenix, Arizona
Multiple Myeloma
View Study & Checklist ➔Plan Development for Giving Teclistamab in the Outpatient Setting
📍 Princess Margaret Cancer Centre — Toronto, Ontario
Multiple Myeloma
View Study & Checklist ➔A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Multiple Myeloma
View Study & Checklist ➔Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
📍 Banner University Medical Center Tucson, University of Arizona — Phoenix, Arizona
Multiple Myeloma
View Study & Checklist ➔Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Recurrent Plasmablastic Lymphoma
View Study & Checklist ➔Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
📍 Emory Winship Cancer Institute — Atlanta, Georgia
Haematological Malignancy
View Study & Checklist ➔A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Multiple Myeloma
View Study & Checklist ➔Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Cytokine Release Syndrome
View Study & Checklist ➔Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania
Recurrent Multiple Myeloma
View Study & Checklist ➔Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
📍 Alliance for Clinical Trials in Oncology — Chicago, Illinois
Plasma Cell Leukemia
View Study & Checklist ➔Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
📍 Colorado Blood Cancer Institute — Denver, Colorado
High-risk Smoldering Multiple Myeloma
View Study & Checklist ➔Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
📍 Arizona Oncology Associates — Tucson, Arizona
Multiple Myeloma
View Study & Checklist ➔Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma
📍 University of Iowa Health Care — Iowa City, Iowa
Multiple Myeloma
View Study & Checklist ➔